
Bridgecom Webinar Spotlights Compliance Success of Kaiser Permanente's Colorectal Cancer Screening Program
Gail Lindsay, R.N., M.A., explains how to implement a formal colorectal cancer disease screening and detection outreach program at former employer Kaiser Permanente Southern California. In her previous role, Lindsay was the co-architect of the Complete Care Program, which employed a centralized approach to holistic care delivery that integrates analytics, care gap prioritization, population health and outreach practices and reporting across diverse disease states, including cancer. Kaiser has performed more than 10 million colorectal cancer screenings since the program's inception. Currently, Lindsay is chief quality officer for the Southern California Region at Providence St. Joseph Health.
Attendees will learn the best colorectal cancer screening methods and recommendations for cohesive screening-specific activities proven to drive patient compliance. Lindsay's programmatic outreach approach also can be applied at organizations to improve outcomes and better manage total costs of care. Healthcare leaders, clinical quality directors, clinicians and other professionals at hospitals and integrated delivery networks, payers and self-insured, large-group employers are invited to the webcast.
WHY: President Clinton declared March as National Colorectal Cancer Awareness Month in February 2000. According to the Colorectal Cancer Alliance, colorectal cancer is the third most commonly diagnosed cancer in the U.S. and is the second leading cause of cancer deaths with women and men combined. An estimated 51,020 deaths from colorectal cancer will occur in 2019.
U.S. Preventive Services Task Force recommends colorectal cancer screening should begin at age 50. An Annals of Internal Medicine study reported Feb. 26 that a single application fecal immunochemical test (FIT) screening can have up to 90 percent sensitivity for colorectal cancer.
TIME & REGISTRATION:
Thursday, March 14, 1-2 p.m. PDT. Click here to register and click here for Gail Lindsay's photo.
Bridgecom is a software and services company that provides healthcare organizations a powerful way to close communication and care gaps. The company's unique blend of technology and patented processes improve patient outcomes and dramatically reduce costs. Bridgecom's immunochemical fecal occult blood test (iFOBT)/FIT at-home test kit works in concert with an integrated platform to help organizations standardize the colorectal cancer screening outreach process. The platform effectively engages patient or member recipients through personalized notifications designed to educate and move them to action achieving compliance. Visit bridgecomsolutions.com .
Media Contact:
Angela Jenkins
Angela Jenkins & Associates
303.877.0115;
Bridgecom Contact:
Brad Hibbard, Vice President, Sales & Marketing
Bridgecom
949.633.3900;
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Most popular stories
Market Reseach
- B2PRIME Strengthens Institutional Team's Growth With Appointment Of Lee Shmuel Goldfarb, Formerly Of Edgewater Markets
- BTCC Exchange Scores Big In TOKEN2049 With Interactive Basketball Booth And Viral Mascot Nakamon
- Ares Joins The Borderless.Xyz Network, Expanding Stablecoin Coverage Across South And Central America
- Primexbt Launches Stock Trading On Metatrader 5
- Solana's First Meta DEX Aggregator Titan Soft-Launches Platform
- Moonacy Protocol Will Sponsor And Participate In Blockchain Life 2025 In Dubai
- Primexbt Launches Instant Crypto-To-USD Exchange
Comments
No comment